Triglyceride-lowering trial neutral for cardiovascular event reduction

A network of molecules and atoms of glass and crystals constitute a single system. 3D illustration

Levels of triglycerides are routinely measured as part of a preventive cardiology work-up and lowering triglycerides with several classes of drugs is common medical practice. Yet, in a major randomized trial of the novel drug pemafibrate, researchers found no reduction in rates of heart attack, stroke, or cardiovascular death over a five-year period, despite the drug lowering triglycerides by 26 percent compared to placebo. The study was led by investigators at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, and included more than 10,000 participants. The new data were presented today at the annual meetings of the American Heart Association Scientific Sessions and published simultaneously in the New England Journal of Medicine.

‘Quordle’ today: Here are the answers and hints for November 7

Previous article

Strategy suggests combining surrogate markers for kidney disease progression in clinical trials

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations